CJC-1295 Peptide (with/without DAC) CAS 863288-34-0

CJC-1295 Peptide – Long-Acting and Short-Acting GHRH Analogues for Endocrine Research

Basic Information

• Product Name: CJC-1295 (with DAC and without DAC)

• CAS Number: 863288-34-0

• Synonyms: CJC-1295, CJC1295

• Purity: ≥98% (HPLC)

• Appearance: White lyophilized powder

• Packaging: Available in vials (e.g., 1 mg, 2 mg, 5 mg, 10 mg)

CJC-1295 with DAC

• Molecular Weight: ~3,447 Da

• Structure: 30‑amino acid peptide amide conjugated to a lipophilic molecule (DAC – Drug Affinity Complex)

• DAC moiety binds to albumin, significantly extending the peptide's half-life to approximately 6–8 days

• Sequence includes four D‑amino acids (D‑Ala, D‑Arg, D‑Leu, D‑His)

CJC-1295 without DAC

• Lacks the DAC moiety, resulting in a shorter half-life (approximately 30 minutes)

• Acts as a fast‑acting GHRH agonist without extended plasma residence

Overview
CJC-1295 is a synthetic analogue of growth hormone‑releasing hormone (GHRH), designed to stimulate the release of growth hormone (GH) from the pituitary gland. It was developed by ConjuChem and evaluated in human trials for the treatment of growth hormone deficiency. The DAC (Drug Affinity Complex) technology covalently binds a lipophilic molecule to the peptide, which reversibly associates with serum albumin, providing a sustained release profile and a prolonged half‑life of 6–8 days.

Mechanism of Action
CJC-1295 binds to the GHRH receptor on pituitary somatotrophs, activating the cAMP signaling pathway, which leads to increased synthesis and secretion of GH. This, in turn, elevates insulin‑like growth factor 1 (IGF‑1) levels. The DAC version provides a sustained GH release profile, while the non‑DAC version offers a shorter burst of GH release.

Key Differences

Applications

• Endocrine research: Studies on GH and IGF‑1 regulation, growth hormone deficiency, and hypothalamic-pituitary function.

• Metabolic research: Investigating obesity, cachexia, and metabolic disorders.

• Aging research: Exploring age‑related decline in GH and IGF‑1 levels and potential interventions.

• Pharmacology: Evaluating the pharmacokinetics and dynamics of GHRH analogues and DAC technology.

• Cell biology: Used in cell culture to study GH‑mediated signaling pathways.

Recommended Use
For research use only. Not for human therapeutic or diagnostic use. Typical in vitro and in vivo dosages should be determined based on specific study protocols. Reconstitute in sterile water or bacteriostatic water as required.

Handling and Storage

• Store lyophilized powder at –20°C in tightly sealed containers, protected from light and moisture.

• After reconstitution, store at –80°C and avoid repeated freeze‑thaw cycles.

• Use appropriate personal protective equipment (gloves, lab coat, safety goggles) when handling.

Quality Assurance
Each batch is tested for purity (by HPLC ≥98%), identity (by mass spectrometry), and sequence confirmation to ensure consistent quality.